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Oregano essential oil (Origanum vulgare L. virens) (OEO) is being used in the food industry due 
to its useful properties to develop new active packaging systems. In this concern, the safety 
assessment of this natural extract is of great interest before being commercialized. The 
European Food Safety Authority requests different in vivo assays to ensure the safety of food 
contact materials. One of these studies is a 90 days repeated-dose oral assay in rodents. In the 
present work, 40 male and 40 female Wistar rats were orally exposed to 50, 100 and 200 
mg/kg body weight (b.w.) OEO during 90 days following the OECD guideline 408. Data revealed 
no mortality and no treatment-related adverse effects of the OEO in food/water consumption, 
body weight, haematology, biochemistry, necropsy, organ weight and histopathology. These 
findings suggest that the oral no-observed-adverse-effect level (NOAEL) of this OEO is 200 
mg/kg b.w. in Wistar rats, the highest dose tested. In conclusion, the use of this OEO in food 
packaging appears to be safe based on the lack of toxicity during the subchronic study at doses 
















Oregano (Origanum vulgare L.) is an aromatic plant with a wide distribution 
throughout the Mediterranean area and Asia (Wei et al., 2016). The composition of oregano 
essential oil (OEO) commonly includes carvacrol, thymol, α-terpinene and ρ-cymene among 
other compounds (Burt et al., 2004). The traditional applications of OEO are related to the 
properties against microorganism and oxidation. Recently, OEO has further application since it 
is recognised as a natural preservative agent with a strong potential for food preservation 
(Muriel-Galet et al., 2015). In this sense, the antimicrobial effect of OEO on food has been 
extensively studied. De Medeiros Barbosa et al. (2016) reported antimicrobial activity of OEO 
combined with rosemary EO at subinhibitory concentrations in fresh leafy vegetables. Also in 
meat, OEO has demonstrated to display an antimicrobial effect alone (Soultos et al., 2009; 
Jayasena and Jo, 2013; Pesavento et al., 2015) and in combination with other EO from clove 
and cinnamon (Radha krishnan et al., 2014). In addition, OEO has been also useful in cheese 
not only as antibacterial (Govaris et al., 2011) but also as antioxidant (Asensio et al., 2015). 
However, the direct addition of OEO may alter the organoleptic characteristics of food and 
influence negatively in its acceptance. In this sense, Van Haute et al. (2016) reported that the 
sensorial properties of the meat/fish marinade with OEO and other EOs (thyme and cinnamon) 
are inevitably affected when the necessary EO concentrations to extend the microbial shelf life 
are applied. Similarly, a concentration of 4% OEO in active packaging gave rise to unacceptable 
oregano smell of fresh beef steaks (Camo et al., 2011). Due to the intense aroma of OEO, it can 
be used in food matrices to provide a balance between sensory acceptability and properties 
exerted by the spice (Cattelan et al., 2015). In order to avoid the direct incorporation of OEO 
into food, the active food packaging is a promising trend that allows using OEO that are 
gradually release from the package to the food (Llana-Ruiz-Cabello et al., 2016a).  
 
The effectiveness of OEO included in food packaging has been confirmed as a 
preservative in food. Previous experiments carried out in our laboratory have checked the 
efficacy of polylactic acid films containing 5 and 10% OEO as antioxidant and against 
microorganism (mainly yeast and molds) in ready-to-eat salads (Llana-Ruiz-Cabello et al., 
2016a). A concentration of at least 1% oregano extract in the active packaging system was 
needed to significantly increase beef display life from 14 to 23 days (Camo et al., 2011). In 
addition, antioxidant and antimicrobial properties of ethylene vinyl alcohol copolymer films 




In fact, OEO containing gelatine films exhibited higher in vitro antimicrobial and antioxidant 
properties than films incorporating lavender EO (Martucci et al., 2015).  
 
Along with the usefulness of OEO, included in active food packaging as preservative, its 
safety should be also confirmed. In this regard, OEO is categorised as ‘generally recognized as 
safe’ (GRAS) by the Food and Drug Administration (Manso et al. 2014) and it is classified as a 
food additive by the European Union (Muriel-Galet et al., 2015). As flavouring, OEO is normally 
used in foods at low concentrations. However, the use of these compounds in other 
applications such as in active packaging may require higher doses that will increase the 
concern regarding exposure to these compounds (Stammati et al., 1999). In addition, 
according to the Commission Regulation (EC) No 450/2009, only substances that are included 
in the Community list of authorised substances may be used in components of active 
packaging. However, no substance has been included in the list so far. Therefore, a 
toxicological assessment is needed. The Guidelines of the Scientific Committee on Food for 
safety assessment of substances used in food contact materials (EFSA, 2016) recommend 
genotoxicity and subchronic studies in the core set of tests. Genotoxicity studies of OEO and its 
components are very scarce (EFSA, 2008). However, in the case of the OEO used in the present 
study the genotoxicity has been evaluated. Results obtained in our laboratory have indicated 
absence of genotoxic effects of this OEO in rats exposed up to 200 mg/kg body weight (b.w.) 
(Llana-Ruiz-Cabello et al., 2016c). Carvacrol and thymol, two of the main components of OEO 
have been also studied. Most of the studies have reported that thymol was neither mutagenic 
nor genotoxic using in vitro assays (Azizan and Blevins, 1995; Stammati et al., 1999; 
Horvathova et al., 2006; Buyukleyla and Rencuzogullari, 2009; Llana-Ruiz-Cabello et al., 2014a; 
Maisanaba et al., 2015). However, contradictory results have been obtained for carvacrol using 
in vitro test. It exhibited mutagenic potential and oxidative damage in DNA in the comet assay 
(Llana-Ruiz-Cabello et al., 2014a). Also, carvacrol showed a weak genotoxic potential on 
L5178Y/Tk± cells (Maisanaba et al., 2015). Similarly, in mammalian cells, a positive response 
was obtained in human lymphocytes through the standard comet assay (Aydin et al., 2005a,b). 
However, other authors have also observed negative results (Stammati et al., 1999; Ündeger 
et al., 2009; Aydin et al., 2014). In order to complete the toxicological assessment of OEO and 
its components in vivo studies are needed, but those dealing the toxicity of OEO are very 
scarce. In the case subchronic studies, no previous experiments have been conducted by the 





Considering all this background, the aim of the present work was to study for the first 
time the subchronic toxicity of OEO, containing carvacrol/thymol (10:1), intended to be used in 
active packaging for food applications, in Wistar rats orally exposed to different concentrations 
of this extract for 90 days. According to the OECD 408 guideline (OECD, 1998), body weight 
and food and water consumption were recorded. Moreover, clinical observation, 
haematological and biochemistry parameters, gross and microscopic pathology were 
performed. 
 
2. Materials and methods 
2.1. Supplies and chemicals 
 Commercial powder neutral gelatine from pork protein (Jesus Navarro S.A., Alicante, 
Spain) was used as the vehicle for the test item in the dosed groups and control group in the 
90-days study. The rest of the chemicals were purchased from Sigma-Aldrich (Madrid, Spain). 
 
2.2. Oregano essential oil analysis 
Oregano essential oil was acquired from El Jarpil® (lot number OR2015) (Almería, 
Spain). It was analysed according to NF ISO 11024 using a Hewlett Packard 5890 
chromatograph interfaced to a Hewlett Packard 5970 Mass selective detector (Hewlett 
Packard, Palo Alto, USA). The gas chromatograph was equipped with a polar column HP 
INNOWAX, of 60 m x 0.25 mm x 0.5 µm film thickness. The oven temperature was held at 60°C 
for 6 min, raised to 250°C at 2°C min−1, and maintained at 250°C for 10 min. Helium was used 
as carrier gas at 22 psi and the injection volume was 1 µL. Compound assignment was achieve 
by single ion monitoring for various homologous series and via comparison with published and 
stored data (NKS Library). In the Table 1 the components found in a percentage above 1% have 
been listed, being the main components carvacrol (55.82%), ρ-cimene (16.39%), thymol 
(5.14%), γ-terpine (4.71%) and β-cariophyllene (2.40%). 
  
2.3. Diets 
In order to select the doses for the 90-day study, the acute oral toxicity study “Up and 




dosage up to 2000 mg/kg b.w. of this OEO administered by gavage, so the median lethal dose 
(LD50) was set above this dose. In addition, a preliminary palatability study evidenced that the 
maximum dose that was accepted by animals when added to neutral gelatine was 200 mg/kg. 
Therefore, the selected doses were calculated by dividing this data by a factor of 2, being the 
doses 50, 100 y 200 mg/kg b.w./day (d). Dietary dose individual formulations were prepared 
according to Mellado-García et al. (2016).  
 
2.4. Animal and experimental design 
The 90-day toxicity study was performed at the Central Service of Experimental 
Animals from the University of Córdoba (SAE, Córdoba, Spain), in accordance with the OECD 
Guideline 408 (OECD, 1998), and was codified as 2015-11-SAE. All animals received human 
care in compliance with the guidelines for the protection of animals used for scientific 
purposes (Directive 2010/63/EU, Decision 2012/707/UE and RD 53/2013). All procedures have 
been approved by the Ethical Animal Experimentation Committee of the University of 
Córdoba, and by the Junta de Andalucía (project no. 05/10/2015-339).  
For the 90-day study, 40 male and 40 female Wistar rats, strain Crl. WI (Han) (type 
outbred rats),  were supplied by Charles River Laboratories S.L. (Kings, NY, USA). Rats were fed 
during the acclimatization period (1 week) with standard laboratory feed (Harlan 2014, Harlan 
Laboratories, Barcelona, Spain) and water ad libitum. During acclimatization, the animals were 
examined by a veterinary surgeon. At the start of dosing, at approximately 8 weeks of age, 
average body weight of the males was 297.5±2.0 g and of the females was 188.7±3.6 g. 
Animals were individually housed in cages. Rats were randomly assigned to groups (10 
rats/sex/group) so that mean body weights were similar for each group. The body weight 
range did not exceed ±20% of the mean weight/sex at beginning of treatment. The 
maintenance conditions are described in Mellado-García et al. (2016). 
 
2.5. Body weight, food and water consumption 
Rats were observed daily, and body weights, food intake, and water consumption were 
recorded weekly. The mean body weights per group and sex were calculated weekly from the 
individual animals. The feed conversion efficiency (FCE) was determined by the ratio of food 





2.6. Haematology and blood chemistry 
Blood samples were collected by intracardiac injection (lightly anesthetized with 
isoflurane). Animals were fasted overnight prior blood collection (week 13). The 
haematological parameters studied are described in Mellado-García et al. (2016). Briefly, the 
haematological parameters evaluated on the automatic hematology analyzer Cell-Dyn 3700 
(Abbot, GMI, MI, USA) were: red blood cell count (RBC), hemoglobin (HGB), hematocrit (HCT), 
mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MHCH), blood platelet count (PLT), red cell volume distribution 
(RDW), white blood cell count (WBC), and differential leucocyte count (Neutrophils (NE), 
Lymphocytes (LY), Monocytes (MO), Eosinophils (EO) and Basophils (BA)). 
The standard serum biochemistry parameters were analysed with an automatic chemistry 
analyzer Cobas 6000 (Roche Diagnostics, IN, USA), to evaluate the following serum 
biochemistry parameters: glucose (GLUC), blood urea nitrogen (BUN), creatinine (CREAT), bile 
acids, total cholesterol (CHOL), triglycerides (TRIGL), aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (ALKP), albumin (ALB), total protein (TOT PROT), 
sodium (Na+) and potassium (K+) ions. 
 
2.7. Necropsy, organ weights and histopathology 
Rats were fasted overnight (approximately 18 h) and deeply anaesthetized with 
isofluorane, then euthanized with carbon dioxide inhalation followed by exsanguinated by 
intracardiac injection. All animals were macroscopically examined as well as the organs after 
extraction. The following tissues and organs were collected and weighed wet in situ after 
dissection: brain, liver, intestine, stomach, lungs, heart, spleen, kidneys, thymus, adrenal 
glands, testes and epididims (males), and uterus with cervix and ovaries (females). 
According to the guideline OECD 408 (OECD, 1998), full histopathology was carried on 
the organs and tissues of all animals in the control and the highest dose (200 mg/kg b.w. OEO) 
groups. Light microscopy examination of liver, kidney, intestine, stomach, lung, heart, and 
testicle/ovary was performed. Samples were first fixed in 10% buffered formalin for 24 h at 
4°C, and then immediately dehydrated in graded series of ethanol, immersed in xylol and 




Afterwards, tissue sections were deparaffinised, rehydrated, stained with haematoxylin and 
eosin, and mounted with Cristal/Mount (Paraplat, Oxford Labware, St. Louis, MO.). 
 
2.8. Statistical analysis 
Continuous variables, including body weight, body weight gain, food and water 
consumption, haematology, clinical chemistry, and organ weight, were summarized using 
standard measures of central tendency and dispersion, mean and standard deviation (SD), and 
were reported by sex and dosage. One-way analysis of variance (ANOVA) was performed to 
test differences in continuous variables. Normality assumption was tested using Kolmogorov-
Sminorv's test. If non-normality, comparison were carried out with Kruskal-Wallis test. If those 
tests were statistically significant, multiple comparisons were performed using Tukey-
Kramer/Dunn's Multiple Comparisons Tests. Differences were considered significant from P < 
0.05. All statistical analysis were carried out using Graph-Pad Instant software 
(GraphPadSoftware Inc., La Jolla, USA). 
 
3. Results 
3.1. Survival and clinical observations 
No mortality occurred during the study. Clinical and ophthalmological examination 
showed no abnormalities in all groups during the test period. Overall, there were no 
remarkable treatment-related changes in behaviour or in locomotor activity during the study 
period. However, one female rat from the control group showed an increase in the scratch 
pattern, so it was euthanized for humane reasons on day 89. Samples of skin from this animal 
were analysed and no alteration was observed. 
 
3.2. Body weight, body weight gain, food consumption, feed conversion efficiency, and water 
consumption 
No significant differences were observed in final body weight, body weight gain or 
total food consumption between rats in any treatment group in comparison to their control 





The mean body weight per week of male and female rats exposed to OEO (50, 100 and 
200 mg/kg b.w./d) was not significantly changed through the experiment (Fig. 1). Similarly, no 
significant changes were observed in % body weight gain in males (Fig. 2a) and females (Fig. 
2b). There was no change in food consumption of animals exposed to OEO for 90 days 
(Supplementary data). Moreover, no consistent differences were recorded in water 
consumption at any dosage group when compared to the control group (Supplementary data). 
 
3.3. Haematology and blood chemistry 
Haematology parameters measured in rats orally exposed to OEO are shown in Table 
3. All parameters remained unaltered except the RDW that underwent a significant decrease in 
females fed with the highest dose (200 mg/kg b.w./d OEO). In addition, no significant 
differences in total and differential leucocyte counts were recorded for rats fed with OEO in 
comparison to the untreated male and female rats (Table 4). 
Clinical biochemistry parameters of rats subchronically exposed to 50, 100 and 200 
mg/kg b.w./d OEO are shown in Table 5. These results revealed only significant differences in 
GLUC levels in male rats exposed to 50 mg/Kg/d OEO that decreased in comparison to the 
control group and in female fed with 200 mg/kg b.w./d OEO that increased when compared to 
the group exposed to 50 mg/Kg/d OEO.  
 
3.4. Necropsy, organ weights and histopathology 
Macroscopic examination of organs and tissues from rats subchronically exposed to 
this OEO revealed no remarkable damage. Moreover, no changes in the organ weight (Table 6) 
were observed except in kidney in female rats, which weight slightly increased in the group 
exposed to 200 mg/kg b.w./d OEO in comparison to rats fed with 100 mg/kg b.w./d OEO. 
Similarly, no significant changes were recorded in the relative organ weight/body weight ratio 
(Table 7). Overall, no changes were observed in the organ weight/brain weight ratio, although 
in ovaries it significantly increased only in female rats exposed to 50 mg/kg b.w./d OEO in 
comparison to the control group (Table 8). 
The histological findings described in liver, kidney, intestine, stomach (Fig. 3) and lung, 
heart and testicle ovary (Fig. 4) of treated rats were similar to those observed in the control 
groups. No remarkable changes were observed in any organ of male and female rats exposed 





4. Discussion  
Food industry is undergoing a renewal to increase the shelf-life of food products by 
developing new food packaging. New preservative compounds are needed to satisfy 
consumers’ demands. The incorporation of OEO in active packaging is under study (Llana-Ruiz-
Cabello et al., 2016a), since it could be a good alternative to synthetic compounds, which have 
presented undesirable side effects (Branen, 1974; Nerin et al., 2006). However, the safety of 
OEO needs to be confirmed for this new use in the food industry. In order to accomplish with 
the requirements suggested by the Scientific Committee on Food for safety assessment of 
substances used in food contact materials (EFSA, 2016), subchronic studies are needed. A 90-
day study in rats with the test material administered via the diet would provide a no-observed-
adverse-effect level (NOAEL) (EFSA, 2008). As far as we know, any in vivo experiments have 
studied the subchronic toxicity of OEO so far. However, in vivo experimental models have been 
widely used to confirm the antimicrobial and antioxidant effects of OEO. Thus, OEO dietary 
supplementation in broilers exhibited a significantly positive effect as growth promoter (Peng 
et al., 2016). In addition, OEO improved antioxidant activity in a similar way than vitamin E in 
pigs (Zhang et al., 2015), and even higher effects than vitamin E by improving the pigs’ 
antioxidant status after subchronic exposure (Zou et al., 2015). Moreover, OEO exhibited a 
protective effect against diquat-induced oxidative injury in intestine of rats (Wei et al., 2016). 
Ranucci et al. (2015) reported that a combination of OEO and sweet chestnut wood extract 
may be useful to increase the pig antioxidant status, to prevent lipid oxidation and, thus, to 
increase meat shelf-life.   
Despite no previous in vivo studies have been conducted to assess the subchronic 
effect of OEO, there are several experiments carried out on other EO such as ginger, turmeric, 
peperina and onion (Liju et al., 2013; Jeena et al., 2014; Escobar et al., 2015; Mellado-García et 
al., 2016), although they are very scarce. In our work the NOAEL was set at 200 mg/kg b.w./d. 
Similar NOAEL, 500 mg/kg b.w./d, have been reported for turmeric and ginger EOs, 460 mg/kg 
b.w./d for peperina EO, and 400 mg/kg b.w./d for the onion OE. Higher NOAELs were found in 
the case of extracts, for the dry spearmint extract a NOAEL of 1948 mg extract/kg b.w./d was 
reported on Sprague-Dawley rats (Lasrado et al., 2015), and in a polyphenolic extract of clove 
buds the NOAEL was 1000 mg/kg b.w./d (Vijayasteltar et al., 2016). In all these studies, no 
remarkable effects were recorded, only in the case of peperina EO there was an increase in 




a dose-response pattern (Escobar et al., 2015). Likewise, in the present study, the subchronic 
oral exposure to OEO did not produce any significant adverse effects in the parameters 
recorded. The subchronic administration of three doses of OEO (50, 100 and 200 mg/kg/d) had 
negligible effect on haematological parameters. The percentage of RDW was the single 
parameter undergoing slight decrease, only in one group and in one gender, which can be 
considered as a marginal change with no biological relevance. Similarly, this parameter was 
reported to significantly decrease in male and female exposed to mung bean, but the authors 
stated that there was no biological significance for this observation (Yao et al., 2015). Also, the 
significant reduction in the RDW of male rats consuming the 7.5% genetically modified (GM) 
pork diet compared to the group of 7.5% non-GM pork diets were not considered to be 
adverse (Zhou et al., 2015).  
Furthermore, the clinical biochemistry results in the present work only evidenced 
significant differences in GLUC in male rats exposed to 50 mg/Kg/d OEO that decreased in 
comparison to the control group and in female fed with 200 mg/Kg/d OEO that increased 
when compared to the group exposed to 50 mg/Kg/d OEO. Taking into account that these 
changes did not follow any pattern since they were neither sex-, dose- nor time-dependent 
they could be considered as not biologically relevant (Pucaj et al., 2011). In fact, the latter 
authors reported increases in GLUC level in female rats exposed during 90 days to 2.5 mg/kg/d 
menaquinone-7 and in males fed with the same dose for 44 days; they considered these 
increases as normal changes. Moreover, GLUC level decreased in male rats fed with 100 
mg/kg/d Proallium AP ®, this change being not biologically significant (Mellado-García et al., 
2016). However, GLUC changes have been also reported to have biological implications. Hence, 
male rats fed with conjugated linoleic acid underwent significant reductions in GLUC after 8 
and 13 weeks of treated and in female after 4 weeks (O’Hagan and Menzel, 2003). These 
reductions were related to the influence on insulin level.  
Besides, no morphological changes were observed in the present work in any of the 
tissues studied. As far as we know, this is the first ultrastructural study carried out in vivo in 
this type of EO. However, several authors have described some morphological changes and 
death cells in different cell lines exposed to OEO from different species. Hence, OEO induced 
apoptosis in the fibroblasts cell line 5RP7 from the concentration of 125 µg/mL, although this 
EO was from a different oregano specie Origanum onites (Bostancioglu et al., 2012). Similarly, 
cell death was observed in the intestinal cell line Caco-2 cells exposed up to 500 μg/mL OEO 
from Origanum vulgare, both apoptosis and necrosis, (Dusan et al., 2006; Savini et al., 2009). 




those used in previous in vitro assays, the higher toxicity observed in the in vitro studies may 
be related to other factors. In this regard, the different experimental model, rats in the case of 
the in vivo study and a human cell line in the case of the in vitro studies, can influence the 
results since differences in metabolism and/or in the bioavailability of the OEO may vary 
substantially (Llana-Ruiz-Cabello et al., 2016a). Moreover, further morphological features were 
reported when Caco-2 cells were exposed to the main components of OEO, thymol and 
carvacrol. Thus, thymol induced lipid degeneration, mitochondrial damage, nucleolar 
segregation as well as apoptosis; and more severe damage was observed for carvacrol such as 
vacuolated cytoplasm, altered organelles and finally cell death in vitro (Llana-Ruiz-Cabello et 
al., 2014b). In addition, cell death has been reported in the hepatic cell line HepG2, with an 
increase in the number of necrotic cells after exposure to thymol, while carvacrol caused death 
cell mainly via apoptosis (Stammati et al., 1999; Yin et al., 2012). Similarly, lung cells A549, 
breast cancer cells MDA-MB231 and fibroblasts cells 5RP7 treated with carvacrol showed some 
apoptotic characteristics as well as morphological changes (Koparal and Zeytinoglu, 2003; 
Arunasree, 2010; Akalin and Incesu, 2011). When comparing the toxicity of OEO and its 
components, carvacrol and thymol have been reported to induce higher damage than the OEO 
in HepG2 cells (Özkan and Erdogan, 2011). However, other authors have reported that no 
single compound seems to be responsible for the cytotoxic effects in Caco-2 cells of the OEO 
but the whole oil extract (Savini et al., 2009). Overall, many aspects influence the toxicity of 
OEO such as the concentration assayed, the different composition of each EO and the 
experimental model used among others. 
Provided the NOAEL of the OEO studied in the present work is 200 mg/kg b.w., it is 
interesting to compare this finding with the real scenario of exposure to consumers. Active 
packaging containing OEO would be very useful to pack ready-to-eat salads (Llana-Ruiz-Cabello 
et al., 2016a). In this packaging, 5.5 g of active film is required to pack 1 kg of lettuce. Active 
film containing 5 and 10% of OEO are both useful as antimicrobial and antioxidant agents 
(Llana-Ruiz-Cabello et al., 2016a). However, the most likely percentage of OEO to be used in 
the packaging would be 5% from an economical and safety point of view, since 10% did not 
increase the effectiveness of the active packaging. Therefore, the maximum concentration that 
could be released from packaging to lettuce would be 0.27 g OEO per kg. Considering that a 
medium consumption of lettuce would be 132.53 g per day 
(http://www.aecosan.msssi.gob.es), the maximum quantity of OEO that could be ingested 
would be 36.4 mg of OEO per person per day.  Considering the worst exposure scenario 




would ingest 12,000 mg of OEO per day in the highest dose (200 mg/kg b.w./d); this would be 
around 330-fold higher than this maximum potential exposure. Therefore, no subchronic toxic 
effects are expected in the consumption of the OEO used in this study with applications in 
active food packaging. 
 
5. Conclusions 
The present study reveals lack of subchronic toxic effects of OEO given on diet to rats 
at doses of 50, 100 and 200 mg/kg b.w./d after 90 days. Male and female rats fed with this 
OEO did not show any change on body weight, food and water consumption, as well as on 
biochemical and haematological parameters. In addition, normal histopathological features 
were observed in all tissues. Therefore, the NOAEL obtained in the present work (200 mg/kg 
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Figure 1. Mean body weights (g) of a) male and b) female rats orally exposed to 50, 100 and 
200 mg/kg b.w./d OEO and control rats for 90 days. 
Figure 2. Mean body weight gain (%) of a) male and b) female rats orally exposed to 50, 100 
and 200 mg/kg b.w./d OEO and control rats for 90-day. 
Figure 3. Histopathological analysis of liver, kidney, intestines and stomach of male (A) and 
female (C) control Wistar rats, and male (B) and female (D) rats subchronically exposed to 200 
mg/kg b.w./d OEO for 90-day (bars= 50µm). Normal hepatic cords and normal hepatocytes 
(He) with polyhedral morphology and rounded central nuclei are observed in liver both in 
control male and female rats (A,C) and rats exposed to the highest dose of OEO. In kidney, 
renal parenchyma with normal glomeruli (GI) and renal tubules are shown for all the groups. 
Intestine of rats exposed to OEO are observed as intestinal villi (Vi) with normal enterocytes 
(A,C). Similarly, well developed villi also appear in control groups (B,D). Gastric mucosa with 
mucosal (Mc) and glandular (Gc) cells apparently normal are shown in all groups. 
Figure 4. Histopathological analysis of lung, heart and testicule/ovary of male (A) and female 
(C) control Wistar rats, and male (B) and female (D) rats subchronically exposed to 200 mg/kg 
b.w./d OEO for 90-day (bars= 50µm). In lung, normal bronchial epithelia with bronchia (Br) and 
alveoli (Al) are observed. No remarkable differences were appreciate in cardiac fibers (Fi) of 
treated (B,D) and untreated groups (A,C). Detail of the testicles of male rats showing normal 
seminiferous tubules (St) and interstitial space (Is) (A) are observed in both groups (A,B); 
Ovaries from rats exposed to OEO remained unaltered in comparison to the control rats, both 






Table 1. Main components of Origanum vulgare L. essential oil. 
Table 2. Effect of 90 days oral exposure to OEO on body weight and food consumption in 
Wistar rats. Values represent the mean ± SD of 10 rats/sex/group. Differences between control 
and treated groups for male and female rats were evaluated by Kruskal-Wallis test (K.W.) or by 
ANOVA test (F values). 
Table 3. Hematology parameters of Wistar male and female rats fed with 50, 100 and 200 
mg/kg b.w./d OEO for 90-days. Values are mean ± SD for 10 rats/sex/group. The differences 
between control and treated groups for male and female rats were evaluated by Kruskal-Wallis 
test (K.W.) or by ANOVA test (F values). *p<0.05 in comparison to control group values. 
Table 4. Differential white blood cells count data of Wistar male and female rats fed with 50, 
100 and 200 mg/kg b.w./d OEO for 90-days. Values are mean ± SD for 10 rats/sex/group. The 
differences between control and treated groups for male and female rats were evaluated by 
Kruskal-Wallis test (K.W.) or by ANOVA test (F values). 
Table 5. Clinical biochemistry of Wistar male and female rats fed with 50, 100 and 200 mg/kg 
b.w./d OEO for 90-days. Values are mean ± SD for 10 rats/sex/group. The differences between 
control and treated groups for male and female rats were evaluated by Kruskal-Wallis test 
(K.W.) or by ANOVA test (F values). The significance levels observed are *p<0.05 in comparison 
to control group values, and # p<0.05 when 50 mg/kg/d and 200 mg/kg/d were compared. 
Table 6. Absolute organ weight of Wistar male and female rats fed with 50, 100 and 200 mg/kg 
b.w./d OEO for 90-day. Values are mean ± SD for 10 rats/sex/group. The differences between 
control and treated groups for male and female rats were evaluated by Kruskal-Wallis test 
(K.W.) or by ANOVA test (F values). & p<0.05 when 100 mg/kg/d and 200 mg/kg/d were 
compared. 
Table 7. Relative organ weight/body weight of Wistar male and female rats fed with 50, 100 
and 200 mg/kg b.w./d OEO for 90-day. Values are mean ± SD for 10 rats/sex/group. The 
differences between control and treated groups for male and female rats were evaluated by 
Kruskal-Wallis test (K.W.) or by ANOVA test (F values).  
Table 8. Relative organ weight/brain weight of Wistar male and female rats fed with 50, 100 
and 200 mg/kg b.w./d OEO for 90-day. Values are mean ± SD for 10 rats/sex/group. The 
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RT : retention time. Only the main components were reported. (>1%) 
RT (min) Compound % 
10,6 -PINENE  1,10 
10,8 -THUYENE 1,69 
17,9 -MYRCENE 1,52 
19,2 -TERPINENE 1,62 
23,5 -TERPINENE  4,71 
25,3 p-CYMENE 16,39 
36,8 1-OCTEN-3-OL 1,50 
47,4 TERPINENE-4-OL 1,33 
47,5 -CARYOPHYLLENE 2,40 
79,8 THYMOL 5,14 









Values are mean ± SD for 10 rats/sex/group. 
F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant. 
 
  MALE FEMALE 
PARAMETERS 
Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4 
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
Inicial body 
weight (g) 
296.9±9.7 296.6±5.9 297.1±11.2 299.5±6.1 185.1 ±9.0 187.0 ±5.1 192.1 ±8.0 190.8 ±7.3 
F(36.3)=0.24 p=0.88; N.S. F(36.3)= 1.90 p=0.42; N.S. 
Final body weight 
(g) 
 512.6±48.6 495.4±29.4 502.2±39.7 514.1 ±25.6 255.5 ±19.3 265.4 ±15.2 261.6 ±12.0 258.9 ±12.5 
F(36.3)=0.58 p=0.63; N.S. F(36.3)=0.77 p=0.94; N.S. 
Body weight gain 
215 ±44.2 198.8 ±26.3 205.1 ±35.7 214.6 ±23.6 70.4±11.4  78.4±12.6 69.5±15.3 68.1±10.2 
F(36.3)=0.58 p=0.63; N.S F(36.3)=1.38 p=0.27; N.S. 
Total feed intake 
(g) 
2195.6±159.4 2101.3±168.8 2096.3±138.3 2128.7±93.8 1362.2±120.3 1468.4±128.1 1424.7±92.7 1406.5±61.7 
F(36.3)=1.02 p=0.40; N.S. F(36.3)=1.79 p=0.17; N.S. 
Feed conversion 
ratio 
10.5±1.8 10.7±0.9 10.4±1.4 10.0±1.0 19.7±3.0 19.0±2.1 21.2±3.7 21.1±3.6 



















RBC: Erythrocyte count; HGB: hemoglobin; HCT: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; PLT: platelet (thrombocyte) count; RDW: red blood cell distribution width; K.W: Kruskal-
Wallis Statistic; N.S.: Not Significant. 
HAEMATOLOGY DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2 Group 3 Group 4 Group 1 Group 2 Group 3 Group 4 
    (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
RBC MEAN 9.1 9.3 9.4 9.4 7.8 7.8 8.0 7.8 
106/µl ST. DEV. 0.6 0.6 0.5 0.6 0.4 0.8 0.4 0.6   
F(36.3)=0.4373 p=0.73; N.S. F(36.3)=0.20 p=0.90; N.S. 
HGB MEAN 13.9 13.9 14.4 14.5 12.8 13.4 14.3 13.0 
g/dL ST. DEV. 0.9 1.0 1.2 0.6 1.8 1.4 0.8 1.5   
KW= 3.05 p=0.39; N.S. KW= 4.74 p=0.19; N.S. 
HCT MEAN 69.9 70.6 71.9 70.6 65.3 65.4 66.8 64.4 
% ST. DEV. 3.0 4.3 3.9 3.0 3.5 5.7 3.2 4.4   
F(36.3)=0.54 p=0.66; N.S. KW= 1.81 p=0.61; N.S. 
MCV MEAN 77.1 75.8 77.0 75.5 83.4 83.6 84.0 83.0 
fL ST. DEV. 2.1 1.9 2.3 2.0 2.3 2.3 1.9 2.1   
F(36.3)=1.42 p=0.25; N.S. F(36.3)=0.29 p=0.83; N.S. 
MCH MEAN 15.4 14.9 15.4 15.5 16.4 17.2 18.0 16.7 
pg ST. DEV. 1.7 1.5 1.6 1.3 2.1 1.4 0.5 1.2   
KW= 1.50 =0.68; N.S. F(36.3)=2.50 p=0.08; N.S. 
MCHC MEAN 20.0 19.6 20.0 20.6 19.6 20.6 19.4 20.1 
g/dL ST. DEV. 1.8 2.0 2.1 1.5 2.2 1.6 6.3 1.5   
KW= 2.50 =0.48; N.S. KW= 2.55 =0.47 ; N.S. 
PLT MEAN 883.3 901.5 1217.1 1142.0 597.8 755.4 834.4 829.1 
103/µl ST. DEV. 256.3 358.0 403.0 418.9 264.2 207.8 135.5 156.8   
KW= 4.75 =0.19; N.S. F(36.3)=2.76 p=0.06; N.S. 
RDW MEAN 16.4 17.1 16.6 16.8 15.5 15.0 15.4 14.3* 
% ST. DEV. 1.4 1.3 0.8 1.3 1.2 0.7 0.8 0.8   















WBC: total leukocyte count; NE: neuthrophil; LY: lymphocyte; MO:monocyte; EO:eosinophil; BA:basophil; 
F: Statistics ANOVA test;  K.W:Kruskal-WallisStatistic; N.S.: Not Significant. 
 
DIFFERENTIAL WHITE BLOOD CELLS COUNT DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4  Group 1 Group 2  Group 3  Group 4  
    (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
WBC MEAN 8.7 10.0 9.4 8.1 6.6 7.6 8.1 11.3 
103/µL ST. DEV. 3.3 6.3 1.6 1.1 2.7 3.5 2.2 8.3   
KW= 2.43 p=0.49; N.S. KW= 2.32 p=0.51; N.S. 
NE MEAN 25.4 35.9 33.7 41.9 21.6 23.1 24.8 32.7 
% ST. DEV. 9.2 12.4 12.5 17.8 18.6 13.9 16.3 16.4   
F(36.3)= 2.58 p=0.07; N.S. KW= 2.17 p=0.54; N.S. 
LY MEAN 65.4 53.8 56.2 48.3 73.5 67.3 68.4 57.1 
% ST. DEV. 11.2 13.4 13.6 16.6 19.6 18.3 16.6 20.7   
KW= 7.01 p=0.07; N.S. KW= 2.94 p=0.40; N.S. 
MO MEAN 4.6 5.3 5.1 3.6 4.3 4.7 4.3 4.9 
% ST. DEV. 2.2 3.3 1.2 2.2 2.4 2.5 1.9 2.6   
F(36.3)= 0.85 p=0.47; N.S. F(36.3)= 0.12 p=0.95; N.S. 
EO MEAN 4.3 4.4 4.5 5.6 1.3 4.2 2.0 3.8 
% ST. DEV. 4.0 1.7 2.5 3.1 0.6 5.1 1.0 2.2   
F(36.3)= 0.40 p=0.75; N.S. F(36.3)= 2.07 p=0.12; N.S. 
BA MEAN 0.4 0.7 0.5 0.6 0.5 0.6 0.5 0.5 
% ST. DEV. 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.3   
F(36.3)= 1.80 p=0.16; N.S. F(36.3)= 0.84 p=0.48; N.S. 
Table 5 
CLINICAL BIOCHEMISTRY DATA SUMMARY  
    MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4  Group 1 Group 2  Group 3  Group 4  
    (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) (0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 N=10 N=10 N=10 N=10 
GLUC MEAN 143.7 122.8* 126.8 129.3 128.5 123.2 129.0 154.3
# 
tmg/dL ST. DEV. 18.1 14.6 11.2 13.3 18.2 17.0 11.2 36.2 
    F(36.3)=3.87 
*p<0.05 F(36.3)=3.79#p<0.05 
UREA MEAN 38.1 38.0 36.5 35.6 41.0 37.7 37.3 36.5 
mg/dl ST. DEV. 4.2 5.3 6.7 3.8 6.5 5.1 4.3 4.8   
F(36.3)=0.54 p=0.66; N.S. F(36.3)=1.41 p=0.25; N.S. 
CREAT MEAN 0.2 0.3 0.3 0.3 0.3 0.3 0.3 0.3 
mg/dL ST. DEV. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 
    F(36.3)=2.30 p=0.09; N.S. F(36.3)=0.63 p=0.60; N.S. 
Bile acids MEAN 36.2 31.5 34.2 25.9 54.7 57.0 54.1 44.4 
µMol ST. DEV. 13.3 13.3 12.9 11.2 20.2 30.6 16.3 32.4 
    F(36.3)=1.24 p=0.31; N.S. KW=1.79 p=0.62; N.S. 
CHOL MEAN 64.9 66.3 67.1 60.9 63.6 59.5 68.8 61.2 
mg/dL ST. DEV. 9.1 9.3 9.8 14.2 12.0 9.8 17.5 8.6 
    KW=2.48 p=0.48; N.S. F(36.3)=1.06 p=0.38; N.S. 
TRIGL MEAN 128.8 100.8 111.8 122.2 63.2 58.1 69.0 66.6 
mg/dL ST. DEV. 58.6 31.3 32.6 59.2 22.4 12.2 15.9 18.3 
    F(36.3)=0.67 p=0.58; N.S. F(36.3)=0.72 p=0.54; N.S. 
AST MEAN 136.2 125.9 109.8 117.9 139.3 118.3 136.4 138.89 
U/L ST. DEV. 33.4 20.9 19.2 31.8 51.9 23.4 35.5 35.0 
    F(36.3)=1.74 p=0.18; N.S. F(36.3)=0.64 p=0.60; N.S. 
ALT MEAN 31.4 35.6 28.5 34.5 31.9 26.8 36.9 37.3 
U/L ST. DEV. 5.4 8.7 6.3 12.7 18.3 10.4 14.9 14.1 
    F(36.3)=1.33 p=0.28; N.S. KW=4.36 p=0.23; N.S. 
ALKP MEAN 62.1 60.8 54.8 51.8 24.0 25.6 24.9 19.7 









GLUC: glucose; BUN: blood urea nitrogen; CREAT: creatinine; Bili-T: Bilirubin, total; CHOL: cholesterol, total; TRIGL: triglycerides; AST: aspartate aminotransferase; ALT: alanine aminotransferase; ALKP: alkaline phosphatase; ALB: albumin;  TOT 
PROT: protein, total; Na+:sodium; K+:potassium. 
F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant 
    KW=6.10 p=0.11; N.S. F(36.3)=2.00 p=0.13; N.S. 
ALB MEAN 3.8 3.6 3.6 3.6 3.8 3.7 4.0 3.8 
g/dl ST. DEV. 0.1 0.2 0.2 0.2 0.4 0.4 0.3 0.3 
    KW=0.44 p=0.93; N.S. KW=2.78 p=0.43; N.S. 
TOT PROT MEAN 6.1 6.1 6.1 6.1 5.8 0.7 6.0 5.7 
g/dl ST. DEV. 0.4 0.2 0.2 0.4 0.4 0.4 0.4 0.4 
    KW=0.06 p=0.30; N.S. F(36.3)=1.09 p=0.36; N.S. 
Na+ MEAN 127.1 127.9 128.6 129.4 126.4 127.8 127.0 126.6 
mmol/L ST. DEV. 3.5 2.5 3.7 3.6 6.1 1.9 2.1 2.6 
    F(36.3)=0.84 p=0.48; N.S. F(36.3)=0.30 p=0.83; N.S. 
K+ MEAN 8.6 8.6 7.9 7.7 6.6 6.5 6.1 5.8 
mmol/L ST. DEV. 1.3 1.1 0.6 0.6 1.1 1.1 0.9 0.7 
    F(36.3)=2.27 p=0.10; N.S. F(36.3)=1.42 p=0.25; N.S. 
Table 6 
 
F: Statistics ANOVA test; K.W: Kruskal-Wallis Statistic; N.S.: Not Significant 
 
ORGAN WEIGHT DATA SUMMARY 
MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
   
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day)     
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 
   
N=10 N=10 N=10 N=10 
BODY W. MEAN 495.2 477.1 485.3 495.7 BODY W. MEAN 246.1 255.0 250.7 247.0 
(g) ST. DEV. 48.6 27.8 36.9 25.8 (g) ST. DEV. 16.3 14.4 41.6 12.5 
F(36.3)=0.61 p=0.61; N.S. F(36.3)=0.82 p=0.49; N.S. 
BRAIN MEAN 2.0 2.0 2.0 2.0 BRAIN MEAN 1.7 1.7 1.7 1.7 
(g) ST. DEV. 0.2 0.2 0.1 0.1 (g) ST. DEV. 0.2 0.2 0.1 0.1 
F(36.3)=0.05 p=0.98; N.S. F(36.3)=0.77 p=0.52; N.S. 
LIVER MEAN 15.7 14.0 14.4 14.8 LIVER MEAN 6.3 6.8 6.9 6.8 
(g) ST. DEV. 2.5 1.4 1.7 1.7 (g) ST. DEV. 0.5 0.8 0.7 0.8 
F(36.3)=1.49 p=0.23; N.S. F(36.3)=1.21 p=0.32; N.S. 
HEART MEAN 1.5 1.4 1.5 1.3 HEART MEAN 0.8 0.9 0.9 0.9 
(g) ST. DEV. 0.2 0.2 0.3 0.1 (g) ST. DEV. 0.1 0.1 0.1 0.1 
   F(36.3)=1.47 p=0.24; N.S.    F(36.3)=1.85 p=0.16; N.S. 
SPLEEN MEAN 0.7 0.8 0.7 0.8 SPLEEN MEAN 0.5 0.5 0.5 0.5 
(g) ST. DEV. 0.1 0.1 0.1 0.2 (g) ST. DEV. 0.0 0.1 0.1 0.1 
F(36.3)=0.94 p=0.43; N.S. KW=0.35 p=0.95; N.S. 
KIDNEYS MEAN 3.3 3.2 3.1 3.2 KIDNEYS MEAN 1.9 2.0 1.9 2.1& 
(g) ST. DEV. 0.4 0.4 0.3 0.2 (g) ST. DEV. 0.2 0.2 0.1 0.2 
   F(36.3)=0.57 p=0.64; N.S. F(36.3)=4.388  &p<0.05 
THYMUS MEAN 0.8 0.7 0.8 0.7 THYMUS MEAN 0.5 0.5 0.6 0.6 
(g) ST. DEV. 0.2 0.2 0.2 0.2 (g) ST. DEV. 0.2 0.2 0.2 0.2 
    F(36.3)=1.10 p=0.35; N.S. F(36.3)=0.67 p=0.58; N.S. 
TESTES MEAN 4.0 3.9 3.9 4.0 UTE./CERV. MEAN 0.9 1.0 0.8 0.7 
(g) ST. DEV. 0.6 0.4 0.4 0.4 (g) ST. DEV. 0.3 0.3 0.2 0.1 
      F(36.3)=0.42 p=0.73; N.S. F(36.3)=2.18 p=0.11; N.S 
EPIDIDIMS MEAN 2.6 2.3 2.1 2.6 OVARIES MEAN 0.5 0.7 0.6 
 
(g) ST. DEV. 0.7 0.7 0.6 0.5 (g) ST. DEV. 0.0 0.1 0.1 
 
    F(36.3)=1.45 p=0.24; N.S. KW=6.23 p=0.10; N.S 
ADRENALS MEAN 0.2 0.2 0.1 0.2 ADRENALS MEAN 0.2 0.2 0.2 0.2 
(g) ST. DEV. 0.1 0.2 0.1 0.1 (g) ST. DEV. 0.1 0.0 0.1 0.1 
KW=2.10 p=0.56; N.S. KW=1.10 p=0.36; N.S 
Table 7 
 
N.S.: Not Significant. 
ORGAN WEIGHT/BODY WEIGHT RATIO DATA SUMMARY 
MALE FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
   
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day)     
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 
   
N=10 N=10 N=10 N=10 
BRAIN MEAN 0.41 0.41 0.41 0.40 BRAIN MEAN 0.59 0.59 0.62 0.60 
(%) ST. DEV. 0.06 0.04 0.04 0.04 (%) ST. DEV. 0.13 0.07 0.07 0.06 
KW=0.73 p=0.87; N.S. F(36.3)=0.29 p=0.84; N.S. 
LIVER MEAN 3.16 2.93 2.96 2.99 LIVER MEAN 2.26 2.43 2.51 2.45 
(%) ST. DEV. 0.39 0.25 0.23 0.25 (%) ST. DEV. 0.15 0.27 0.24 0.32 
F(36.3)=1.31 p=0.29; N.S. F(36.3)=1.81 p=0.16; N.S. 
HEART MEAN 0.30 0.30 0.30 0.27 HEART MEAN 0.30 0.34 0.34 0.32 
(%) ST. DEV. 0.04 0.03 0.04 0.02 (%) ST. DEV. 0.03 0.05 0.04 0.05 
   F(36.3)=1.97 p=0.14; N.S.    F(36.3)=1.62 p=0.20; N.S. 
SPLEEN MEAN 0.15 0.16 0.15 0.16 SPLEEN MEAN 0.18 0.19 0.19 0.17 
(%) ST. DEV. 0.02 0.02 0.02 0.03 (%) ST. DEV. 0.02 0.04 0.04 0.04 
   F(36.3)=1.00 p=0.40; N.S. F(36.3)=0.46 p=0.71; N.S. 
KIDNEYS MEAN 0.67 0.67 0.65 0.64 KIDNEYS MEAN 0.68 0.71 0.69 0.77 
(%) ST. DEV. 0.07 0.08 0.05 0.04 (%) ST. DEV. 0.05 0.11 0.07 0.12 
F(36.3)=0.79 p=0.51; N.S. F(36.3)=1.70 p=0.18; N.S. 
THYMUS MEAN 0.17 0.14 0.16 0.15 THYMUS MEAN 0.18 0.19 0.23 0.20 
(%) ST. DEV. 0.05 0.04 0.04 0.05 (%) ST. DEV. 0.07 0.05 0.06 0.06 
    F(36.3)=0.86 p=0.47; N.S. F(36.3)=0.99 p=0.41; N.S. 
TESTES MEAN 0.82 0.82 0.80 0.82 UTE./CERV. MEAN 0.33 0.36 0.29 0.27 
(%) ST. DEV. 0.13 0.08 0.08 0.07 (%) ST. DEV. 0.11 0.11 0.09 0.06 
      F(36.3)=0.11 p=0.95; N.S. F(36.3)=1.63 p=0.20; N.S. 
EPIDIDIMS MEAN 0.53 0.48 0.44 0.52 OVARIES MEAN 0.19 0.23 0.21 0.19 
(%) ST. DEV. 0.13 0.15 0.15 0.10 (%) ST. DEV. 0.02 0.04 0.04 0.04 
KW=2.84 p=0.42; N.S. F(36.3)=2.90 p=0.05; N.S. 
ADRENALS MEAN 0.04 0.05 0.03 0.04 ADRENALS MEAN 0.07 0.07 0.08 0.08 
(%) ST. DEV. 0.02 0.04 0.02 0.01 (%) ST. DEV. 0.02 0.02 0.02 0.03 
KW=2.30 p=0.51; N.S. F(36.3)=1.41 p=0.26; N.S. 
Table 8 
N.S.: No Significant. 
ORGAN WEIGHT/BRAIN WEIGHT RATIO DATA SUMMARY 
MALE  FEMALE 
    Group 1 Group 2  Group 3  Group 4        Group 1 Group 2  Group 3  Group 4  
   
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day)     
(0 mg/Kg/day) (50 mg/Kg/day) (100 mg/Kg/day) (200 mg/Kg/day) 
    N=10 N=10 N=10 N=10 
   
N=10 N=10 N=10 N=10 
LIVER MEAN 789.8 715.2 731.6 755.4 LIVER MEAN 360.2 389.8 405.0 411.7 
(%) ST. DEV. 137.3 101.7 103.8 121.6 (%) ST. DEV. 33.6 39.6 41.6 54.8 
F(36.3)=0.77 p=0.52; N.S. F(36.3)=2.60 p=0.07; N.S. 
HEART MEAN 74.1 73.6 74.2 68.3 HEART MEAN 48.2 58.0 52.5 52.9 
(%) ST. DEV. 11.3 10.0 15.6 8.1 (%) ST. DEV. 8.8 11.6 6.8 5.1 
   F(36.3)=0.62 p=0.61; N.S.    F(36.3)=2.13 p=0.12; N.S. 
SPLEEN MEAN 36.8 38.6 36.4 40.7 SPLEEN MEAN 29.3 32.3 30.2 29.4 
(%) ST. DEV. 8.1 6.2 6.2 8.6 (%) ST. DEV. 2.9 6.6 5.4 6.1 
   F(36.3)=0.71 p=0.55; N.S. F(36.3)=0.62 p=0.61; N.S. 
KIDNEYS MEAN 167.6 164.1 159.5 161.6 KIDNEYS MEAN 109.3 123.4 110.6 128.5 
(%) ST. DEV. 26.8 28.9 20.1 17.5 (%) ST. DEV. 13.7 35.9 7.1 18.2 
F(36.3)=0.21 p=0.89; N.S. F(36.3)=1.85 p=0.16; N.S. 
THYMUS MEAN 41.9 33.5 39.2 37.0 THYMUS MEAN 31.4 32.6 36.6 33.9 
(%) ST. DEV. 11.5 9.0 8.8 12.6 (%) ST. DEV. 11.3 9.9 10.1 9.5 
    F(36.3)=1.13 p=0.35; N.S. F(36.3)=0.48 p=0.70; N.S. 
TESTES MEAN 194.1 199.5 195.9 207.2 UTE./CERV. MEAN 56.3 59.8 46.3 45.6 
(%) ST. DEV. 28.8 24.5 20.2 29.4 (%) ST. DEV. 17.5 14.3 12.6 10.1 
    F(36.3)=0.48 p=0.70; N.S. F(36.3)=2.63 p=0.06; N.S. 
EPIDIDIMS MEAN 132.0 117.4 108.5 130.6 OVARIES MEAN 30.6 39.9* 33.7 32.7 
(%) ST. DEV. 31.1 40.5 34.1 25.0 (%) ST. DEV. 2.4 8.9 6.7 6.1 
    F(36.3)=1.14 p=0.34; N.S.       F(36.3)=3.62 *p<0.05 
ADRENALS MEAN 10.9 8.2 7.4 8.7 ADRENALS MEAN 11.5 12.5 13.6 13.2 
(%) ST. DEV. 5.7 2.9 4.0 3.3 (%) ST. DEV. 3.6 3.3 4.0 4.9 
F(36.3)=1.35 p=0.27; N.S. F(36.3)=0.54 p=0.66; N.S. 
